Italy’s suspension of a special batch was tied to a person in Sicily who died after receiving his shot. It’s unclear whether or not a blood clot was concerned.
More than 142,000 individuals in Denmark, which has a inhabitants of about six million, have been injected with the vaccine produced by AstraZeneca.
The Danish minister of well being, Magnus Heunicke, said on Twitter that it’s “currently not possible to conclude whether there is a connection.” He added. “We acted early, it needs to be thoroughly investigated.”
Denmark had already scaled again the goal for ending its immunization marketing campaign partially as a result of of delays in deliveries. The security pause will delay it additional.
AstraZeneca’s vaccine got here underneath scrutiny over potential questions of safety final year whereas it was being examined in medical trials. Two vaccinated volunteers in Britain developed neurological signs in line with transverse myelitis, an inflammatory syndrome that impacts the spinal wire and is usually brought on by viral infections.
Those issues quickly shut down world trials of the vaccine, however investigations finally discovered no proof linking the signs to the vaccine. One of the individuals who fell ailing was later discovered to have an undiagnosed case of a number of sclerosis.
More than 70 international locations have since approved the vaccine, with the notable exception of the United States, the place regulators are ready on information from a big medical trial there anticipated within the subsequent few weeks. A choice from the Food and Drug Administration on whether or not to authorize AstraZeneca’s vaccine is probably going greater than a month away.
The most in depth real-world information on the vaccine’s security comes from Britain, which had administered 9.7 million doses via final month. The British drug regulator, the Medicines and Healthcare Products Regulatory Agency, mentioned “the number and nature of suspected adverse reactions reported so far are not unusual in comparison to other types of routinely used vaccines.”
Rebecca Robbins reported from Bellingham, Wash., and Thomas Erdbrink from Amsterdam. Jason Horowitz and Emma Bubola contributed reporting from Italy, Benjamin Mueller from London and Denise Grady from New York.